此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项研究观察通过饮食和运动治疗的 2 型糖尿病患者与安慰剂相比,CagriSema 能降低多少血糖和体重 (REIMAGINE 1)

2026年9月28日 更新者:Novo Nordisk A/S

卡格林肽和索马鲁肽 (CagriSema) 皮下注射联合给药的功效和安全性在饮食和运动控制不充分的 2 型糖尿病参与者中,每周一次 2.4 mg/2.4 mg 和 1.0 mg/1.0 mg 剂量与安慰剂相比

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

研究概览

研究类型

介入性

注册 (实际的)

189

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100853
        • Chinese People's Liberation Army General Hospital-Endocrinology
    • Jiangsu
      • Nanjing、Jiangsu、中国、210011
        • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
      • Zhenjiang、Jiangsu、中国、212001
        • The Affiliated Hospital of Jiangsu University-Endocrinology
    • Shandong
      • Ji'Nan、Shandong、中国、250000
        • Jinan Central Hospital
      • Jinan、Shandong、中国、250000
        • Jinan Central Hospital
      • Budapest、匈牙利、1032
        • Szent Margit Rendelőintézet Nonprofit Kft.
      • Budapest、匈牙利、1102
        • PVN Kutató Kft.
    • Hajdú-Bihar
      • Debrecen、Hajdú-Bihar、匈牙利、4025
        • Belinus Bt.
    • Szabolcs-Szatmar Varmegye
      • Nyíregyháza、Szabolcs-Szatmar Varmegye、匈牙利、4405
        • Borbánya Praxis E.Ü. Kft.
      • Belgrade、塞尔维亚、11080
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade、塞尔维亚、11080
        • Clinical Hospital Centre Zemun
      • Belgrade、塞尔维亚、11000
        • CHC Zvezdara, Clinical department for endocrinology
      • Zaječar、塞尔维亚、19000
        • Policlinic for diabetes
      • Bergamo、意大利、24127
        • Azienda Ospedaliera Papa Giovanni XXIII
      • Catanzaro、意大利、88100
        • Policlinico Mater Domini Università di Catanzaro
      • Milan、意大利、20132
        • IRCCS Ospedale San Raffaele Milano
      • Roma、意大利、00161
        • Azienda Ospealiero Universitaria Policlinico Umberto I
      • Al Ahsa、沙特阿拉伯、36428
        • King Abdulaziz Hospital-Al Ahsa-National Guard
      • Jeddah、沙特阿拉伯、21423
        • National Guard Hospital - Jeddah
      • Riyadh、沙特阿拉伯、11525
        • King Fahad Medical City
      • Riyadh、沙特阿拉伯、12372
        • King Khaled University Hospital,King Saud Univ. Med. City
      • Riyadh、沙特阿拉伯、12769
        • King Salman Bin Abdulaziz Hospital
      • Bialystok、波兰、15-351
        • Osteo-Medic s.c. A. Racewicz, J. Supronik
      • Bialystok、波兰、15-797
        • Renew Clinic Sp. z o.o.
      • Lodz、波兰、90-338
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
      • Warsaw、波兰、02-507
        • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
      • Warsaw、波兰、00-710
        • NBR Polska Tomasz Klodawski
      • Zamość、波兰、22-400
        • Velocity Nova Sp. z o.o.
    • Podkarpackie Voivodeship
      • Rzeszów、Podkarpackie Voivodeship、波兰、35-055
        • Centrum Medyczne Medyk Sp. z o.o.
    • California
      • Huntington Park、California、美国、90255
        • Nat Res Inst Huntington Park
      • Northridge、California、美国、91325
        • Valley Clinical Trials, Inc.
      • Santa Ana、California、美国、92701
        • Southern California Dermatology
    • Florida
      • Hollywood、Florida、美国、33024
        • Encore Medical Research LLC
      • Orlando、Florida、美国、32819
        • Headlands Research Orlando
      • Weston、Florida、美国、33331
        • Encore Medical Research of Weston
    • Kansas
      • Newton、Kansas、美国、67114
        • Alliance for Multispec Res
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Brigham & Women's Hospital
    • Michigan
      • Troy、Michigan、美国、48098
        • Arcturus HC PLC Troy Med Res
    • New York
      • West Seneca、New York、美国、14224
        • Southgate Medical Group, LLP
    • Oregon
      • Portland、Oregon、美国、97210
        • Summit Research Network Oregon Inc.
    • Tennessee
      • Kingsport、Tennessee、美国、37660
        • Holston Medical Group
    • Texas
      • Amarillo、Texas、美国、79124
        • Amarillo Medical Specialists
      • Austin、Texas、美国、78704
        • Elligo Clin Res Centre
      • Brownsville、Texas、美国、78526
        • Headlands Research Brownsville
      • Dallas、Texas、美国、75230
        • Velocity Clinical Res-Dallas
      • San Antonio、Texas、美国、78233
        • Northeast Clinical Research of San Antonio
      • Shavano Park、Texas、美国、78231
        • Consano Clinical Research, LLC
      • Sugar Land、Texas、美国、77479
        • Sugar Lakes Family Practice PA
      • Weslaco、Texas、美国、78596
        • Valley Diab. & Endo Comp Ctr
    • Virginia
      • Newport News、Virginia、美国、23606
        • TPMG Clinical Research

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female
  • Age 18 years or above at the time of signing the informed consent
  • Diagnosed with type 2 diabetes >=30 days before screening
  • HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
  • Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
  • Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
  • Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
有源比较器:CagriSema Dose 2

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

安慰剂比较:Placebo Dose 2

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

有源比较器:Cagrisema Dose 1

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

安慰剂比较:Placebo Dose 1

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in glycated haemoglobin (HbA1c)
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as percentage (%)-points.

From baseline (week 0) to end of treatment (week 40)

次要结果测量

结果测量
措施说明
大体时间
Relative change in body weight
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured in %.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=15% body weight reduction
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
大体时间:At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
大体时间:At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Change in Fasting Plasma Glucose (FPG)
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured in millimoles per liter (mmol/L).

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=5% body weight reduction
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=20% body weight reduction
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Change in waist circumference
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured in centimeters (cm).

From baseline (week 0) to end of treatment (week 40)
Change in systolic blood pressure (SBP)
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured in millimeters of mercury (mmHg).

From baseline (week 0) to end of treatment (week 40)
Change in diastolic blood pressure (DBP)
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured in mmHg.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Total cholesterol
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Triglycerides
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Free fatty acids
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Non-HDL cholesterol
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
大体时间:At end of study (week 52)

Measured as count of participants.

At end of study (week 52)
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10.

Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Physical Component Summary score
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Mental Component Summary score
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7.

From baseline (week 0) to end of treatment (week 40)
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36).

From baseline (week 0) to end of treatment (week 40)
Change in leptin
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured in nanograms per milliliter (ng/mL).

From baseline (week 0) to end of treatment (week 40)
Change in soluble leptin receptor
大体时间:From baseline (week 0) to end of treatment (week 40)

Measured in ng/mL.

From baseline (week 0) to end of treatment (week 40)
Number of Treatment Emergent Adverse Events (TEAEs)
大体时间:From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of events.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
大体时间:From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
大体时间:From baseline (week 0) to end of treatment + 7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment + 7 weeks (week 47)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Transparency (dept. 2834)、Novo Nordisk A/S

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年3月19日

初级完成 (实际的)

2025年10月1日

研究完成 (实际的)

2025年12月22日

研究注册日期

首次提交

2024年3月15日

首先提交符合 QC 标准的

2024年3月15日

首次发布 (实际的)

2024年3月21日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • NN9388-4895
  • 2022-502677-42 (其他标识符:European Medical Agency (EMA))
  • U1111-1283-0404 (其他标识符:World Health Organization (WHO))

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅